Human Lymphocyte Antigen 9 (LY9) RTU ELISA Kit | LY9 rtu elisa kit

Human Lymphocyte Antigen 9 (LY9) ELISA Kit

Cat. Num. AAA4500878

• Gene Names: LY9; hly9; mLY9; CD229; SLAMF3
• Reactivity: Human
• Synonyms: Lymphocyte Antigen 9 (LY9); Human Lymphocyte Antigen 9 (LY9) ELISA Kit; RASI-1; MMP18; Occasionally Referred To As Stromelysin-4; LY9 rtu elisa kit

• Reactivity: Human
• Sequence Length: 193

• Assay Type: Sandwich
• Samples: Tissue Homogenates, Cell Lysates or Other Biological Fluids.
• Detection Range: 0.312-20ng/mL
• Sensitivity: 0.128ng/mL
• RTU ELISA Kit's Advantage: The Ready-To-Use (RTU) Kits require fewer steps in setup and take less time to run. Detection Solutions are pre-diluted and total incubation time is shorter than many other ELISA Kits.
• Preparation and Storage: For unopened kits: All the reagents should be kept at 4 degree C upon receipt.; For opened kits: Once the kit is opened, the remaining reagents still need to be stored according to the above storage conditions. In addition, return the unused wells to the foil pouch containing the desiccant pack and reseal along entire edge of zip-seal.

Typical Testing Data/Standard Curve (for reference only)

Related Product Information for LY9 rtu elisa kit

Test Principle: The microtiter plate provided in this kit has been pre-coated with an antibody specific to LY9. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody preparation specific to LY9. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain LY9, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of LY9 in the samples is then determined by comparing the O.D. of the samples to the standard curve.

NCBI and Uniprot Product Information

• NCBI GI #: 75991709
• NCBI GeneID: 4063
• NCBI Accession #: NP_001028839.1
• NCBI GenBank Nucleotide #: NM_001033667.2
• UniProt Accession #: Q9HBG7; Q14775; Q5VYI3; Q6P2J4; Q9H4N5; Q9NQ24; A8K7N3
• Molecular Weight: 71,961 Da
• NCBI Official Full Name: T-lymphocyte surface antigen Ly-9 isoform b
• NCBI Official Synonym Full Names: lymphocyte antigen 9
• NCBI Official Symbol: LY9
• NCBI Official Synonym Symbols: hly9; mLY9; CD229; SLAMF3
• NCBI Protein Information: T-lymphocyte surface antigen Ly-9
• UniProt Protein Name: T-lymphocyte surface antigen Ly-9
• Protein Family: T-lymphocyte surface antigen
• UniProt Gene Name: LY9
• UniProt Synonym Gene Names: SLAMF3

NCBI Description

LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008]

Uniprot Description

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. May participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A (PubMed:22184727). Promotes recruitment of RORC to the IL-17 promoter (PubMed:22989874). May be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. May disable autoantibody responses and inhibit IFN-gamma secretion by CD4+ T-cells. May negatively regulate the size of thymic innate CD8+ T-cells and the development of invariant natural killer T (iNKT) cells ().